FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM

Shares of NeuroDerm Ltd. (NDRM) rose more than 26% on Wednesday, following positive results from its phase II trial of ND0612H for advanced Parkinson's disease.

from RTT - Biotech http://ift.tt/2lC66Xa
via IFTTT